TipRanks
Fisher & Paykel Healthcare Corporation Limited (DE:FPLB)
FRANKFURT:FPLB
Germany Market
FPLB
Fisher & Paykel Healthcare Corporation Limited
RESEARCH TOOLSreports

Fisher & Paykel Healthcare Corporation Limited (FPLB) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

FPLB Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Fisher
& Paykel Healthcare Corporation Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FPLB Stock 12 Month Forecast

Average Price Target

€25.11
▲(13.10% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Fisher & Paykel Healthcare Corporation Limited in the last 3 months. The average price target is €25.11 with a high forecast of €26.87 and a low forecast of €20.96. The average price target represents a 13.10% change from the last price of €22.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"€16","27":"€27","18.75":"€18.75","21.5":"€21.5","24.25":"€24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26.8712402,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€26.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.10845454,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€25.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.958588,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,18.75,21.5,24.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,22.55932616923077,22.918652338461538,23.277978507692307,23.637304676923076,23.996630846153845,24.355957015384615,24.715283184615384,25.074609353846153,25.433935523076922,25.79326169230769,26.15258786153846,26.51191403076923,{"y":26.8712402,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,22.42372727230769,22.647454544615385,22.871181816923077,23.094909089230768,23.31863636153846,23.542363633846154,23.766090906153845,23.989818178461537,24.21354545076923,24.437272723076923,24.660999995384614,24.88472726769231,{"y":25.10845454,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.2,22.104506769230767,22.009013538461538,21.913520307692306,21.818027076923077,21.722533846153844,21.627040615384615,21.531547384615383,21.436054153846154,21.34056092307692,21.245067692307693,21.14957446153846,21.054081230769228,{"y":20.958588,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.295,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.196,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.098,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.196,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.403,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.096,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.382,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.007,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.809,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.601,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€26.87Average Price Target€25.11Lowest Price Target€20.96
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:FPLB
Craig Wong-Pan
RBC Capital
RBC Capital
€19.46→€25.95
Buy
16.89%
Upside
Upgraded
09/15/26
Fisher & Paykel Healthcare upgraded to Outperform at RBC CapitalFisher & Paykel Healthcare upgraded to Outperform at RBC Capital
Citi Analyst forecast on DE:FPLB
Laura Sutcliffe
Citi
Citi
€19.96→€25.45
Buy
14.64%
Upside
Upgraded
09/10/26
Positive Report for Fisher & Paykel Healthcare Corporation Limited (FSPKF) from Citi
Jefferies Analyst forecast on DE:FPLB
Vanessa Thomson
Jefferies
Jefferies
€26.31
Buy
18.53%
Upside
Reiterated
09/01/26
Jefferies Keeps Their Buy Rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
J.P. Morgan Analyst forecast on DE:FPLB
Chris Cooper
J.P. Morgan
J.P. Morgan
€26.87
Buy
21.04%
Upside
Reiterated
08/24/26
J.P. Morgan Remains a Buy on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Morgan Stanley Analyst forecast on DE:FPLB
David Bailey
Morgan Stanley
Morgan Stanley
―
Buy
―
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Jarden Analyst forecast on DE:FPLB
Adrian Allbon
Jarden
Jarden
―
Hold
―
Reiterated
08/24/26
Analysts Conflicted on These Healthcare Names: Ramsay Health Care (Other OTC: RMSYF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Macquarie Analyst forecast on DE:FPLB
Unknown Analyst
Macquarie
Not Ranked
Macquarie
―
Buy
―
Reiterated
08/23/26
UBS Analyst forecast on DE:FPLB
Marcus Curley
UBS
UBS
€18.71→€20.96
Hold
-5.59%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Warby Parker (NYSE: WRBY), Viatris (NASDAQ: VTRS) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Canaccord Genuity Analyst forecast on DE:FPLB
Shane Storey
Canaccord Genuity
Canaccord Genuity
€22.6
Buy
1.80%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Rapid Micro Biosystems (RPID), Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Goldman Sachs Analyst forecast on DE:FPLB
Davinthra Thillainathan
Goldman Sachs
Goldman Sachs
€26.5→€27.3
Buy
22.99%
Upside
Reiterated
02/23/26
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Vir Biotechnology (NASDAQ: VIR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:FPLB
Craig Wong-Pan
RBC Capital
RBC Capital
€19.46→€25.95
Buy
16.89%
Upside
Upgraded
09/15/26
Fisher & Paykel Healthcare upgraded to Outperform at RBC CapitalFisher & Paykel Healthcare upgraded to Outperform at RBC Capital
Citi Analyst forecast on DE:FPLB
Laura Sutcliffe
Citi
Citi
€19.96→€25.45
Buy
14.64%
Upside
Upgraded
09/10/26
Positive Report for Fisher & Paykel Healthcare Corporation Limited (FSPKF) from Citi
Jefferies Analyst forecast on DE:FPLB
Vanessa Thomson
Jefferies
Jefferies
€26.31
Buy
18.53%
Upside
Reiterated
09/01/26
Jefferies Keeps Their Buy Rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
J.P. Morgan Analyst forecast on DE:FPLB
Chris Cooper
J.P. Morgan
J.P. Morgan
€26.87
Buy
21.04%
Upside
Reiterated
08/24/26
J.P. Morgan Remains a Buy on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Morgan Stanley Analyst forecast on DE:FPLB
David Bailey
Morgan Stanley
Morgan Stanley
―
Buy
―
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Jarden Analyst forecast on DE:FPLB
Adrian Allbon
Jarden
Jarden
―
Hold
―
Reiterated
08/24/26
Analysts Conflicted on These Healthcare Names: Ramsay Health Care (Other OTC: RMSYF) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Macquarie Analyst forecast on DE:FPLB
Unknown Analyst
Macquarie
Not Ranked
Macquarie
―
Buy
―
Reiterated
08/23/26
UBS Analyst forecast on DE:FPLB
Marcus Curley
UBS
UBS
€18.71→€20.96
Hold
-5.59%
Downside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Warby Parker (NYSE: WRBY), Viatris (NASDAQ: VTRS) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Canaccord Genuity Analyst forecast on DE:FPLB
Shane Storey
Canaccord Genuity
Canaccord Genuity
€22.6
Buy
1.80%
Upside
Reiterated
05/27/26
Analysts Are Bullish on Top Healthcare Stocks: Rapid Micro Biosystems (RPID), Fisher & Paykel Healthcare Corporation Limited (FSPKF)
Goldman Sachs Analyst forecast on DE:FPLB
Davinthra Thillainathan
Goldman Sachs
Goldman Sachs
€26.5→€27.3
Buy
22.99%
Upside
Reiterated
02/23/26
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Vir Biotechnology (NASDAQ: VIR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
ASNDAscendis Pharma
HROWHarrow Health
IRTCIrhythm Technologies
DNLIDenali Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fisher & Paykel Healthcare Corporation Limited

3 Months
Chris CooperJ.P. Morgan
Success Rate
5/6 ratings generated profit
83%
Average Return
+14.52%
Copying Chris Cooper's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +14.52% per trade.
1 Year
Shane StoreyCanaccord Genuity
Success Rate
8/9 ratings generated profit
89%
Average Return
+16.39%
Copying Shane Storey's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +16.39% per trade.
2 Years
Davinthra ThillainathanGoldman Sachs
Success Rate
5/5 ratings generated profit
100%
Average Return
+28.02%
Copying Davinthra Thillainathan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +28.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FPLB Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
8
8
9
5
8
Hold
5
5
7
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
13
16
11
14
In the current month, FPLB has received 8 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. FPLB average Analyst price target in the past 3 months is 25.11.
Each month's total comprises the sum of three months' worth of ratings.

FPLB Financial Forecast

FPLB Earnings Forecast

Next quarter’s earnings estimate for FPLB is €0.24 with a range of €0.24 to €0.24. The previous quarter’s EPS was €0.22. FPLB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FPLB has Performed in-line its overall industry.
Next quarter’s earnings estimate for FPLB is €0.24 with a range of €0.24 to €0.24. The previous quarter’s EPS was €0.22. FPLB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FPLB has Performed in-line its overall industry.

FPLB Sales Forecast

Next quarter’s sales forecast for FPLB is €626.10M with a range of €624.22M to €626.74M. The previous quarter’s sales results were €625.94M. FPLB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FPLB has Performed in-line its overall industry.
Next quarter’s sales forecast for FPLB is €626.10M with a range of €624.22M to €626.74M. The previous quarter’s sales results were €625.94M. FPLB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FPLB has Performed in-line its overall industry.

FPLB Stock Forecast FAQ

What is DE:FPLB’s average 12-month price target, according to analysts?
Based on analyst ratings, Fisher & Paykel Healthcare Corporation Limited’s 12-month average price target is 25.11.
    What is DE:FPLB’s upside potential, based on the analysts’ average price target?
    Fisher & Paykel Healthcare Corporation Limited has 13.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Fisher & Paykel Healthcare Corporation Limited a Buy, Sell or Hold?
          Fisher & Paykel Healthcare Corporation Limited has a consensus rating of Strong Buy, which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Fisher & Paykel Healthcare Corporation Limited’s share price target?
            The average share price target for Fisher & Paykel Healthcare Corporation Limited is 25.11. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €26.87 ,and the lowest forecast is €20.96. The average share price target represents 13.10% Increase from the current price of €22.2.
              What do analysts say about Fisher & Paykel Healthcare Corporation Limited?
              Fisher & Paykel Healthcare Corporation Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Fisher & Paykel Healthcare Corporation Limited?
                To buy shares of DE:FPLB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.